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Dynamic-arc respiratory-gated stereotactic radiotherapy 
 — technique presentation
Grzegorz Woźniak1, Łukasz Dolla2, Krzysztof Ślosarek2, 3, Barbara Bekman2,  
Tomasz Latusek1, Grzegorz Głowacki1
Main advancements in radiation treatment in recent years have included the introduction of dynamic techniques 
and 4D radiotherapy. The treatment of movable tumors relies on two important techniques: gating and tracking. 
The limitation of the former is the relatively short duration of the respiratory phase during which the radiation can 
be delivered and the need to teach the patient to breathe in accordance with the correct pattern. At the same time, 
certain clinical situations require the use of dynamic techniques. Intensity modulated radiotherapy (IMRT), combined 
with gantry rotation, forms the basis for the VMAT technique. The procedure usually takes a shorter time to complete 
than other dynamic techniques, which considerably improves patient comfort. The recently introduced True BeamTM 
accelerator employs all the latest innovations in terms of dose-rate modeling and respiratory gating. 
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Description of the method
Respiratory-gated stereotactic radiotherapy with the 
use of the dynamic arcs (RA — Rapid Arc®) technique, im-
plemented in daily practice at the Gliwice center, requires 
additional patient preparation procedures. These involve pa-
tient immobilization, respiratory phase imaging, the delin-
eation of target volume and critical structures with respect 
to the selected breathing phase, radiotherapy planning, and 
relevant dosimetric measurements.
Patients are immobilized on the table with the aid of 
vacuum mattresses, which are easy to employ, can be reused 
multiple times, and do not restrict respiratory movements, 
in contrast to devices such as thermoplastic masks, for in-
stance. In theory, radiotherapy can be performed without 
patient immobilization, but mattresses help reduce torso 
bending and rotation and thus considerably improve pa-
tient comfort during a procedure that can often take up to 
an hour to complete.
The most important preliminary stage involves the de-
tection and imaging of the appropriate respiratory phase 
with a Siemens Somatom CT scanner. Scans are usually 
taken at intervals of 1–3 mm, both before and after the 
radiocontrast is administered, and 4D radiotherapy is made 
possible by a detection system that relies on an infrared 
camera to register respiratory movements by tracking the 
displacements of a metaplex slab phantom with six fluores-
cent markers inserted near the epigastric region. The RPM 
(Real-time Positioning Management) system analyzes and 
records the patient’s breathing pattern as a sinusoid that 
indicates the point of maximum inhalation and exhalation. 
Based on this curve, an appropriate respiratory phase is then 
selected for therapy. The final exhalation phase is usually 
considered the longest and the most stable; accordingly, this 
is when treatment is administered. To guarantee the accu-
racy of the CT image reconstruction for each phase, which 
affects the quality of the final scan, it is essential to make sure 
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that the patient’s breathing is stable and regular. Since the 
RPM system allows for manual adjustment, slight breathing 
anomalies can be disregarded. If greater disruptions occur, 
however, the test should be stopped and repeated.
The CT lab of the Treatment Planning Unit uses a re-
trospective respiratory-gated CT testing method, which 
means that the entire respiratory phase is scanned; the 
RPM system first records a breathing curve for the patient, 
which then serves as the basis for selecting the appropriate 
phase for image processing and reconstruction. If doubts 
arise with respect to the exact size of the target volume, an 
additional MRI scan is performed. MRI tests are very advan-
tageous, especially in liver tumors, but also show important 
limitations in terms of subsequent fusion with CT scans. As 
they require a special coil, they cannot be performed with 
the aid of immobilization mattresses. In addition, imaging 
sequences in MRI are longer than in CT, which leads to mo-
tion-related image distortions. Despite the gating options 
currently in use, organ locations in MRI scans often fail to 
match completely with those in CT images, which causes 
discrepancies during subsequent fusion.
Based on CT scans and their fusion with MRI images, 
target volumes and critical organs are then delineated, and 
the treatment plan is elaborated. 
Alongside standard radiation energies, the Varian True-
BeamTM linear accelerator also includes two flattening fil-
ter-free beams of 6 and 10 MV, which allow to generate 
dose rates of 1400 MU/min and 2400 MU/min, respectively. 
In addition, the high speed of the multileaf collimator (MLC) 
and the option of planning based on the arc technique 
with dose rate modulation have made it possible to use the 
VMAT (volumetric modulated arc therapy) in 4D radiotherapy. 
Several arcs are usually used, mainly due to the limited num-
ber of monitor units that can be measured during a single 
gantry rotation cycle. In addition, multiple arcs that differ in 
collimator angles often yield more accurate isodose curves, 
because of the greater variety of MLC leaf positions.
For every plan prepared with the volumetric modulated 
arc technique (VMAT), the dose distribution should be veri-
fied through dosimetry before the treatment is initiated. This 
is done with the aid of Sun Nuclear’s ArcCheck® cylindrical 
multidetector array, which allows to carry out accurate mea-
surements and reconstruct the 3D dose distribution pattern 
in the phantom. Due to its submilimeter accuracy, additional 
equipment geometry tests are also required before every 
radiotherapy session. Apart from standard accelerator effi-
ciency tests, a modified Winston-Lutz test is carried out to 
control the position of the isocenter of the gantry and the 
correlated isocenter of the OBI image verification system 
with maximum precision.
Once the patient has been immobilized on the table, 
verification scans are taken. As a standard practice, two 
kilovoltage orthogonal X-ray projections are used. The True-
BeamTM accelerator allows to coordinate imaging time with 
the previously selected respiratory phase (and the DRR 
image generated by the treatment planning system). This 
allows to avoid respiratory motion-related discrepancies in 
reference point location. Another verification method relies 
on CBCT (cone beam computer tomography), which involves 
taking CT scans in the area of interest with a cone beam of 
orthovoltage X-rays. The OBI system generator fixed to the 
arm of the treatment device completes a single rotation 
around the patient; the kilovoltage beam is recorded as it 
penetrates the tissues, processed, and converted into a CT 
image. A lower exposure than that of classical computer to-
mography is enough to yield a image. The 3D reconstruction 
of CT scans significantly improves the accuracy of stereo-
tactic radiotherapy, especially when the treatment table 
permits rotary movement [1]. However, the longer total 
scanning time considerably limits the application of CBCT 
in respiratory-gated radiotherapy, since the images cannot 
be taken in the same respiratory phase. For this reason, the 
system is not commonly used in this form of treatment.
Treatment delivery is automatic. During rotation by 
a fixed angle, radiation exposure is only switched on in the 
pre-defined breathing phase, i.e. when the tumor is located 
within the field of the radiation beam. Radiation is suspen-
ded once breathing moves on to the next phase and the 
gantry is moved back, so that it can deliver radiation again 
during the next respiratory cycle and move by a further 
angle down the pre-defined arc. The movement of the slab 
phantom placed in the epigastric region is tracked in three 
dimensions by infrared cameras throughout the procedure. 
If breathing anomalies exceed accepted tolerance limits, 
treatment is stopped until correct breathing is restored. 
Importantly, flattening filter-free (FFF) VMAT treatment in-
volves a high-intensity dose that changes with the changing 
rotational speed of the accelerator’s arm. This significantly 
shortens the procedure time in comparison with conformal 
radiotherapy techniques. 
Discussion
Stereotactic radiotherapy (SR) is currently recogni-
zed as one of the most effective radiation treatment me-
thods [2, 3]. Initially used in the treatment of benign intra-
cranial tumors (Gamma Knife) [4], it is now emoloyed in 
a variety of intracranial and extracranial cancers. Indications 
for stereotactic therapy include primary, relapsed (also 
benign), and secondary brain tumors that do not qualify 
for surgery [5–10]. Extracranially, SR is used to treat small, 
sharply delineated tumors in various parts of the body, 
including primary tumors and metastatic lymph nodes in 
the head and neck area, tumors of the chest, abdomen, and 
pelvis (especially the prostate gland), as well as lesions fo-
und in limbs and bones [3, 11–14]. In the case of respiratory 
moving tumors, the technique can be successfully applied 
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in the treatment of lung and liver cancers, often constituting 
an alternative to radical surgery or palliative care [2, 15–18]. 
Tumors located in organs affected by respiratory motion on 
both sides of the diaphragm (mediastinum, kidneys, adre-
nal glands, spleen) can also be treated with radiosurgery 
with the use of respiratory gating or tracking [19–22]. The 
basic limitation of the method is the size and location of the 
tumor. Delivering a single high dose of radiation to a small 
tumor volume often has the biological effect comparable 
to its surgical ablation (hence the term radiosurgery or 
radioablation) [23–25]. High doses, however, are equally 
dangerous to healthy tissues, which means they can only be 
used for small tumors (usually up to 4 cm). A greater target 
volume means that more healthy tissues will absorb the 
beam and treatment toxicity will increase. Tumor location 
and the possibility of delivering high radiation doses near 
critical structures constitute another significant limitation 
of stereotactic therapy. The risk of geographical error can 
be reduced through the key procedures of patient immobi-
lization and position verification [26]. In addition, dynamic 
techniques (IMRS, VMAT) allow to accurately modulate dose 
distributions, achieve high dose gradients, and escalate the 
dose in tumors near vital organs [27, 28]. The use of image-
-guided verification (IGRT — image guided radiotherapy) 
often provides a very accurate estimate of tumor location 
with respect to anatomical structures that should be pro-
tected with particular attention. 
Technologies generating energetically homogeneous 
beams have been perfected over many years, based on the 
premise that tumor cells are evenly distributed and show 
similar radiation sensitivity [29–31]. In order to cause uni-
form and even damage to these cells, the argument went, 
an even and uniform beam of radiation should be delivered. 
Successive years, however, delivered new data, indicating 
that clonogenic tumor cells distribution is not homogenous 
and show varying degrees of radiosensitivity determined 
by different biological phenomena, such as hypoxia [31]. 
Accordingly, constructors of radiotherapy equipment no 
longer tried to generate a uniform radiation beam; to the 
contrary, new technologies relied on pre-existing heteroge-
neous dose distributions or even deliberately created them 
by altering (modulating) beam intensity.
In any accelerator, electrons stopped on the anode 
shield generate a heterogeneous radiation beam: the dose 
is highest near the axis and decreases as the beam radiates 
away. The beam profile is often uniformized by a cone fil-
ter, which results in a flattened, uniform dose distribution 
throughout the area delimited by the collimator jaws [32]. 
Unfortunately, the procedure always involves the weak-
ening of radiation intensity and a decrease in dose rates. 
In contrast, using multileaf collimators to modulate the 
beam profile makes it possible to achieve a non-uniform 
dose distribution in target volumes of any shape. One of 
the chief drawbacks of this technique (IMRT) has to do with 
long exposure times due to the small size of radiation fields 
(a larger field is divided into smaller beams that change over 
time) [33]. Changes in the approach to dose heterogeneity 
also altered the way in which new accelerators are construct-
ed. Instead of using a cone filter to model a uniform radiation 
beam in the collimator, the cone was removed and the beam 
is modified as it leaves the shield. Removing the filter, which 
normally absorbs a large portion of initial radiation (from 
50 to 90%), allows to achieve a high dose intensity, which 
in turn shortens exposure times (FFF beams). 
Two techniques are used in the radiotherapy of mo-
tion-dependent areas: gating and tracking [34, 35]. The 
main limitation of the former is the relatively short duration 
(gate) of the respiratory phase during which the dose can 
be delivered. Low dose rates and the insufficient speed of 
MLC leaves in earlier accelerators limited the application 
of dynamic techniques in respiratory gating. Thanks to the 
high doses generated in filter-free accelerator heads, a high 
amount of energy can now be delivered in a short time (as 
short as the respiratory gate), which makes it potentially 
available for use in gating.
The TrueBeamTM accelerator allows to use FFF beams 
(FFF — flattening filter free) with dose rates of up to 2400 
MU/min (in a standard cone-filter accelerator, the cor-
responding value equals 600 MU/min). In addition, the 
use of the VMAT (or RapidArc® technology in the Varian 
company nomenclature), which combines gantry rotation 
over partial or complete arcs with the modulation of dose 
rates and collimator leaf movement, allows to deliver gated 
radiotherapy through a dynamic technique.
The RPM RapidArc® method shares all the advantages 
and drawbacks of other dynamic techniques. In some cas-
es, conformal plans yield similar target volume and critical 
structure parameters, while requiring less time to com-
plete. The VMAT technique, however, makes it possible to 
treat several neighboring tumors based on the same ref-
erence point, that is difficult in conformal techniques and 
often proves impossible, especially if the goal is to deliver 
a different dose to each tumor. The VMAT technique shows 
a significant advantage in the treatment of tumors situated 
near critical structures, but higher efficiency in this case is 
usually achieved at the expense of lower dose uniformity 
and a greater volume of healthy tissues that absorb radi-
ation. The VMAT technique is particularly beneficial when 
a HD collimator (with leaf width of 2.5 mm) can be used to 
fine-tune the shape of the beam to match the spatial form 
of the tumor.
The essential advantage of the VMAT technique has to 
do with procedure duration. Using FFF beams with high 
dose rates considerably reduces effective radiation time. 
Thanks to varying dose intensity (delivery time decreases 
two- to fourfold), it can be reduced by as much as 30%. 
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The difference is keenly felt by the patient, especially when 
several tumors are treated at the same time. Shorter the-
rapy sessions should be viewed from the perspective of 
treatment precision.
In the case of the FFF-VMAT technique, verification of pa-
tient’s set up takes longer because the system can take scans 
only in certain phases of the respiratory cycle, which means 
that, in a sense, it needs to “wait” for the patient to start bre-
athing along a specific pre-defined pattern. In addition, the 
time is extended if respiratory anomalies occur; in this case, 
treatment is suspended until normal breathing is restored.
Conclusion
To sum up, respiratory-gated radiotherapy is a common-
ly recognized treatment method for lung and liver cancers, 
which may also be successfully used in other tumors located 
near the diaphragm. The proximity of critical organs in the 
treatment area often makes VMAT radiotherapy a valuable 
treatment option and even a necessity if patient comfort 
and safety are to be ensured.
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